[The effect of sufentanil on acute lung injury in rabbits].
OBJECTIVE
To study the effect of sufentanil on acute lung injury induced by hemorrhagic shock in rabbits.


METHODS
Fifty-four healthy rabbits were randomly divided into three groups: control group,with only incision of trachea; model group, hemorrhagic shock was produced according to modified Wiggers' method; sufentanil group, intravenous injection of sufentanil at 0.02 microg x kg(-1) x h(-1) after hemorrhagic shock. To all the rabbits, intravenous Ringer lactate solution was given in an amount of 5 ml x kg(-1) x h(-1). Mean arterial pressure (MAP), heart rate (HR) and plasma tumor necrosis factor-alpha (TNF-alpha) were determined before shock, 1, 2, 3 and 4 hours after resuscitation. Malondialdehyde (MDA) and water content of lungs were measured 1, 2 and 4 hours after resuscitation.


RESULTS
At same time points, MAP and HR in sufentanil group and model group were lower than that in control group (P<0.05) but contents of TNF-alpha in serum, MDA in lung tissue and water content of lungs were elevated gradually. The degree of decrease or increase was less obvious in sufentanil than in model group (P<0.05 or P<0.01).


CONCLUSIONS
Hemorrhagic shock could increase arterial plasma TNF-alpha content with lung injury. Sufentanil could alleviate acute lung injury induced by hemorrhagic shock in rabbits.
Zhang
Cheng-Ming
CM
Department of Anesthesiology, Affiliated Hospital of Weifang Medical College, Weifang 261042, Shandong, China.
Yu
Jin-Ling
JL
Zhang
Yan
Y
Chen
Li-Xia
LX
Cao
Huan-Jun
HJ
Wang
Yu-Ying
YY
D055371:Acute Lung Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D008168:Lung / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011817:Rabbits; D011897:Random Allocation; D012771:Shock, Hemorrhagic / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D017409:Sufentanil / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde; D017409:Sufentanil